Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
- Final approval from the European Commission expected within the next few months
Jul 25th, 2008 - The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the anticoagulant rivaroxaban (Xarelto®), taken as one tablet, once-daily, for the prevention of venous blood clots in patients undergoing elective (planned) hip or knee replacement surgery. It is expected that final approval by the European Commission will follow in the next few months, providing marketing authorization for rivaroxaban in all EU member states. Rivaroxaban was invented in Bayer’s Wuppertal laboratories in Germany, and is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
“The recommendation for approval of rivaroxaban by the CHMP marks another significant milestone in our extensive development program. We received it only nine months after the submission – very fast compared to average,” said Dr. Kemal Malik, member of the Bayer HealthCare Executive Committee, responsible for product development. “Rivaroxaban has demonstrated its significant clinical potential in a ground-breaking study program and we are looking forward to providing this innovative treatment alternative to patients in Europe very soon.”
“The limitations of current treatment standards mean that many orthopaedic surgery patients still do not receive satisfactory anticoagulant therapy to prevent potentially fatal blood clots,” commented Dr. Bengt Eriksson, Orthopaedic Surgeon at the Sahlgrenska University Hospital/Östra, Gothenburg, Sweden, and Principal Investigator of the RECORD1 clinical trial. “The results of the rivaroxaban Phase III RECORD studies are indeed very positive and rivaroxaban has the potential to change standard practice in the prevention of deep vein thrombosis and pulmonary embolism.”
The positive opinion was received from the CHMP after the Committee reviewed data from the extensive RECORD clinical program that included three Phase III trials of rivaroxaban involving nearly 10,000 patients undergoing elective hip or knee replacement surgery (RECORD1, 2 and 3 trials). Results from these three studies demonstrated the superior efficacy of rivaroxaban, both in head-to-head comparisons with enoxaparin (RECORD1 and 3), and when comparing extended-duration (5 weeks) rivaroxaban with short-duration (2 weeks) enoxaparin (RECORD2). In all three trials, rivaroxaban and enoxaparin had comparable safety profiles including similar low rates of major bleeding.
To date, Bayer HealthCare has submitted regulatory filings in more than 10 other countries, including Canada and China. Rivaroxaban is expected to be filed for approval in the U.S. shortly, and on approval, Ortho-McNeil, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., will market the drug in the U.S.
The extensive clinical trial program supporting rivaroxaban makes it the most studied oral direct Factor Xa inhibitor in the world today. Almost 50,000 patients are expected to be enrolled overall into the rivaroxaban clinical development program which will evaluate the product in the prevention and treatment of a broad range of acute and chronic bloodclotting disorders such as VTE treatment, stroke prevention in patients with atrial fibrillation, VTE prevention in hospitalized, medically ill patients and secondary prevention of acute coronary syndrome.
In the EU, there are in excess of 1.5 million blood clot events annually and these are responsible for killing 544,000 people each year – more than breast cancer, prostate cancer, HIV/AIDS and road traffic accidents combined. Please visit www.thrombosisadviser.com to learn more about VTE.
Bayer estimates the global peak sales potential of rivaroxaban for all indications to exceed EUR 2 billion.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports to the Frankfurt Stock Exchange and in our reports filed with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
- Formation of a clot inside a blood vessel.
- The ability of a drug to produce the desired effect.
- Acute coronary syndrome
- An umbrella term used to cover any group of clinical symptoms compatible with an acute heart attack. The subtypes of acute coronary syndrome include unstable angina (in which the heart muscle is not damaged), and two forms of heart attack in which the heart muscle is damaged. These latter types are named according to the appearance of the electrocardiogram as non-ST segment elevation myocardial infarction (NSTEMI) and ST segment elevation myocardial infarction (STEMI).
- Atrial fibrillation
- A heart rhythm disorder where chambers in the upper heart (atria) beat more rapidly than those in the lower section of the heart. Blood is not pumped out of the upper chambers completely during beating, and may pool and form a clot. A stroke results if a section of clot dislodges from the upper chambers and becomes lodged in the brain.
- Factor Xa
- Pivotal component of blood clotting cascade. Stimulates the production of thrombin, the enzyme in the coagulation cascade that promotes the formation of blood clots.
- Venous thromboembolism
- A disease process beginning with a blood clot occurring within the venous system, including deep vein thrombosis and pulmonary embolism.